Imlifidase vor Nierentransplantation bei hochsensibilisierten Kindern (DINKY)
Eine einarmige, multizentrische Studie zur Bewertung der Wirksamkeit und Sicherheit von Imlifidase bei hochsensibilisierten Kindern (1-17 Jahre), die eine Nierentransplantation mit positiver Kreuzprobe gegen einen lebenden oder verstorbenen Spender erhalten, der nach der Behandlung mit Imlifidase in einen negativen umgewandelt wurde
The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD).
The main questions it aims to answer are:
- Does imlifidase treatment result in crossmatch conversion that enables transplantation?
- How is the function of the transplanted kidney?
The participants will be hospitalised in accordance with the normal routines for transplanted patients. The patients will receive medication to prevent rejection of the donor kidney, and because such treatment make the body more vulnerable medications to prevent infections.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
After being informed about the study and potential risks, all patients giving written informed consent will undergo pre-screening to determine eligibility for study entry.
The trial will include highly sensitised ESRD paediatric patients (1-17 years). The patients have previously undergone desensitization unsuccessfully or have an anti-HLA antibody status deemed too difficult to make a successful desensitization using other experimental methods.
A screening visit will take place when an organ offer has been placed for a final check of the patients' eligibility for study participation.
All patients included in the trial will be desensitized with imlifidase to convert the positive XM to negative and then transplanted with either a kidney from a deceased donor (DD) or a living donor (LD).
Patients will be hospitalised in accordance with the normal routines for transplanted patients at each clinic.
Following transplantation, the patients will receive induction therapies, rejection prophylaxis, and maintenance immunosuppressive therapies.
The patients will be closely monitored for any signs of antibody-mediated rejections (AMRs).
The duration of the interventional trial period after an organ has been offered will be 6 months for each patient. The trial includes a follow-up part to collect long-term efficacy and safety data up to 5 years after the transplantation.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Central Contact
- Telefonnummer: +46 46 16 56 70
- E-Mail: clinicalstudyinfo@hansabiopharma.com
Studienorte
-
-
-
Helsinki, Finnland, 00290
- Zurückgezogen
- HUS, Helsinki University Hospital
-
-
-
-
-
Paris, Frankreich, 75019
- Rekrutierung
- Robert Debre University Hospital
-
Kontakt:
- Julien Hogan, Professor
- E-Mail: julien.hogan2@aphp.fr
-
Hauptermittler:
- Julien Hogan, Professor
-
-
-
-
-
Rome, Italien, 00165
- Noch keine Rekrutierung
- Ospedale Pediatrico Bambino Gesu
-
Kontakt:
- Raffaella Labbadia, MD
- E-Mail: ctc@opbg.net
-
Hauptermittler:
- Raffaella Labbadia, MD
-
-
-
-
Stockholm County
-
Huddinge, Stockholm County, Schweden, SE-141 86
- Rekrutierung
- Karolinska University Hospital
-
Kontakt:
- L Wennberg, MD
- E-Mail: Lars.Wennberg@regionstockholm.se
-
Hauptermittler:
- L Wennberg, MD
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekrutierung
- Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica
-
Hauptermittler:
- Gema Ariceta, MD
-
Kontakt:
- Gema Ariceta, MD
- E-Mail: gema.ariceta@vallhebron.cat
-
Barcelona, Spanien, 08950
- Noch keine Rekrutierung
- Hospital Sant Joan De Deu Barcelona
-
Kontakt:
- Yolanda Calzada, MD
- E-Mail: frecerca.startup@sjd.es
-
Hauptermittler:
- Yolanda Calzada, MD
-
-
-
-
-
London, Vereinigtes Königreich, WC1N 3JH
- Rekrutierung
- Great Ormond Street Hospital for Children NHS Foundation Trust
-
Kontakt:
- S Marks, MD
-
Hauptermittler:
- S Marks, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Signed Informed Consent obtained from patient/parent/legal guardian/independent witness (depending on patient's age) before any trial-related procedures
- Highly sensitised patient with panel reactive antibodies (PRA) ≥80%
- Male or female patient between the age of 1 to 17 years (up to the day before the 18th birthday) at the time of screening
- Patient with end-stage renal disease (ESRD) and waiting for a renal transplant from a living or deceased donor
- Patient must be transplantable (including size mismatch) at the time of obtaining informed consent for trial participation
- Patients who have previously undergone desensitisation unsuccessfully with plasmapheresis/IVIg/anti-CD20 or have an anti-HLA antibody status deemed too difficult to make a successful desensitisation (judgement based on physicians' previous experience with similar patients)
- Positive crossmatch (XM) test determined by flow cytometry crossmatch (FCXM) and/or complement-dependent cytotoxicity crossmatch (CDCXM) tests against the donor. For the DD patients, if physical XM tests are not practically possible due to lack of time, patients may be included on a virtual crossmatch (vXM) predictive of a positive XM test.
- Willingness and ability to comply with the protocol as judged by the investigator
Exclusion Criteria:
- Previous treatment with imlifidase
- IVIg treatment within 28 days prior to imlifidase treatment
- Desensitisation treatment(s) within 1 month prior to the current transplantation
- Hypersensitivity to the active substance (imlifidase) or to any of the excipients and to other immunosuppressive drugs specified in the protocol
- Ongoing serious infections
- Present, or history of, thrombotic thrombocytopenic purpura (TTP), or known familial history of TTP
- At the time of transplantation: severe other condition requiring treatment and close monitoring e.g. cardiac failure ≥ grade 4 (New York Heart Association), unstable coronary disease, active peripheral vascular disease, proven hypercoagulable conditions/events or oxygen dependent respiratory disease
- Malignancy within 3 years prior to transplantation
- ABO blood group incompatible transplantations (A2 and A2B kidneys will not be accepted for B recipients)
- Any other reason that, in the view of the investigator, precludes transplantation
- Breast feeding or pregnancy, if applicable
- Woman of fertile age and sexually active without adequate contraceptive measures to avoid pregnancy during the interventional trial period (i.e. up to 6 months after transplantation)
- Suspicion of Covid-19 infection or positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test
- Positive serology for human immunodeficiency virus (HIV)
- Clinical signs of hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), or Epstein Barr virus (EBV) infection
- Donor with positive serology for HIV, HBV, HCV or CMV to a patient with negative serology (mismatch serology). Mismatch serology for EBV in accordance with center specific standard procedures for transplantation of EBV negative recipients and at investigator's discretion.
- Clinically relevant active infection(s) as judged by the investigator
- Tuberculosis or history of tuberculosis
- Use of other investigational agents within 5 terminal elimination half-lives prior to the transplantation
- Contemporaneous participation in medical device studies
- Known mental incapacity or language barriers precluding patients'/parents'/legal guardians' adequate understanding of the informed consent information and the trial activities
- Inability by the judgement of the investigator to participate in the trial for any other reason
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Imlifidase
Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes within 24 hours prior to transplantation. |
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of patients with conversion of a positive crossmatch test to negative within 24 hours after start of imlifidase treatment
Zeitfenster: From start of imlifidase administration to 24 hours
|
Immunoglobulins (IgG) including donor specific antibodies (DSAs) are rapidly and efficiently cleaved by imlifidase. A conversion of a positive to a negative XM will enable transplantation. |
From start of imlifidase administration to 24 hours
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Transplantatüberleben (Todeszensierung) bis zu 5 Jahre nach Transplantation
Zeitfenster: Von 6 Monaten bis zu 5 Jahren
|
Von 6 Monaten bis zu 5 Jahren
|
|
|
Transplantatversagensfreies Überleben bis zu 5 Jahre nach der Transplantation
Zeitfenster: Von 6 Monaten bis zu 5 Jahren
|
Von 6 Monaten bis zu 5 Jahren
|
|
|
Patientenüberleben bis zu 5 Jahre nach Transplantation
Zeitfenster: Von 6 Monaten bis zu 5 Jahren
|
Von 6 Monaten bis zu 5 Jahren
|
|
|
Anteil der Patienten mit Dialysepflicht bis 5 Jahre nach Transplantation
Zeitfenster: Von 6 Monaten bis zu 5 Jahren
|
Von 6 Monaten bis zu 5 Jahren
|
|
|
Renal function up to 5 years after transplantation as assessed by estimated glomerular filtration rate (eGFR)
Zeitfenster: From pre-dose imlifidase up to 5 years
|
eGFR is a measure of kidney function. Reduced kidney function is characterised by a decreased eGFR value. |
From pre-dose imlifidase up to 5 years
|
|
Renal function up to 5 years after transplantation as assessed by serum/plasma creatinine levels
Zeitfenster: From pre-dose imlifidase up to 5 years
|
Creatinine is a measure of kidney function. Reduced kidney function is characterised by an increased value. |
From pre-dose imlifidase up to 5 years
|
|
Renal function up to 5 years after transplantation as assessed by serum/plasma cystatin C levels
Zeitfenster: From pre-dose imlifidase up to 5 years
|
Cystatin C is a measure of kidney function. Reduced kidney function is characterised by an increased value. |
From pre-dose imlifidase up to 5 years
|
|
Renal function up to 5 years after transplantation as assessed by proteinuria
Zeitfenster: From pre-dose imlifidase up to 5 years
|
Proteinuria (protein/creatinine ratio in urine) is a measure of kidney function. Reduced kidney function is characterised by an increased value. |
From pre-dose imlifidase up to 5 years
|
|
DSA levels up to 5 years after transplantation
Zeitfenster: From pre-dose imlifidase up to 5 years
|
Donor specific antibodies (DSAs) are antibodies in the recipient directed against the transplanted organ. |
From pre-dose imlifidase up to 5 years
|
|
Frequency of delayed graft function (DGF)
Zeitfenster: From transplantation up 7 days after transplantation
|
DGF is defined as 'Need for dialysis within 7 days of transplantation' in "Delayed graft function in kidney transplantation: developing drugs for prevention, guidance for industry", FDA 2019. Frequency of patients having DGF in accordance with this definition will be presented. |
From transplantation up 7 days after transplantation
|
|
Length of DGF
Zeitfenster: From transplantation up 7 days after transplantation
|
DGF is defined as 'Need for dialysis within 7 days of transplantation' in "Delayed graft function in kidney transplantation: developing drugs for prevention, guidance for industry", FDA 2019. The duration of DGFs in accordance with this definition will be presented. |
From transplantation up 7 days after transplantation
|
|
Imlifidase Pharmacokinetics (AUC)
Zeitfenster: From pre-dose imlifidase up to Day 15
|
AUC = Area under the imlifidase plasma concentration versus time curve. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (Cmax)
Zeitfenster: From pre-dose imlifidase up to Day 15
|
Cmax = Maximum observed plasma concentration of imlifidase following dosing. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (tmax)
Zeitfenster: From pre-dose imlifidase up to Day 15
|
tmax = Time point for maximum observed plasma concentration of imlifidase following dosing |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (t1/2)
Zeitfenster: From pre-dose imlifidase up to Day 15
|
t1/2 = Terminal half-life of imlifidase. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (CL)
Zeitfenster: From pre-dose imlifidase up to Day 15
|
CL = Clearance of imlifidase. |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacokinetics (Vz)
Zeitfenster: From pre-dose imlifidase up to Day 15
|
Vz = Volume of distribution during the elimination phase |
From pre-dose imlifidase up to Day 15
|
|
Imlifidase Pharmacodynamic (PD) profile up to 9 days after imlifidase treatment
Zeitfenster: From pre-dose imlifidase up to Day 10
|
PD is assessed as serum concentrations of intact IgG and its fractions following infusion. |
From pre-dose imlifidase up to Day 10
|
|
Immunogenicity profile of imlifidase up to 5 years after imlifidase treatment
Zeitfenster: From pre-dose imlifidase up to 5 years
|
Immunogenicity is assessed as serum concentration of anti-imlifidase IgG (ADA). |
From pre-dose imlifidase up to 5 years
|
|
Proportion of patients with biopsy- and serology (DSA)-confirmed AMR up to 5 years after transplantation
Zeitfenster: From transplantation up to 5 years
|
Banff scores (Loupy et al. 2020) will be used for biopsy evaluation. |
From transplantation up to 5 years
|
|
Proportion of patients with biopsy confirmed cell-mediated rejection (CMR) up to 5 years after transplantation
Zeitfenster: From transplantation up to 5 years
|
Banff scores (Loupy et al. 2020) will be used for biopsy evaluation. |
From transplantation up to 5 years
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Sicherheit bewertet als Anteil der Patienten mit infusionsbedingten Reaktionen innerhalb von 48 Stunden nach der Imlifidase-Infusion
Zeitfenster: Ab Beginn der Imlifidase-Infusion bis zu 48 Stunden
|
Ab Beginn der Imlifidase-Infusion bis zu 48 Stunden
|
|
Sicherheit, die innerhalb von 30 Tagen nach der IMLIFIDASE -Behandlung als Anteil der Patienten mit schweren oder schwerwiegenden Infektionen bewertet wurde
Zeitfenster: Von Beginn der Imlifidase -Infusion bis zu 30 Tage
|
Von Beginn der Imlifidase -Infusion bis zu 30 Tage
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Clinical Operations, Hansa Biopharma AB
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Pathologische Prozesse
- Männliche Urogenitalerkrankungen
- Nierenerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Chronische Erkrankung
- Krankheitsattribute
- Niereninsuffizienz
- Niereninsuffizienz, chronisch
- Pathologische Zustände, Anzeichen und Symptome
- Nierenversagen, chronisch
- MAC-1-ähnliches Protein, Streptococcus
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 20-HMedIdes-21
- 2022-500230-28-00 (Andere Kennung: EU Trial Number)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .